Gri Bio Etf Performance

GRI Etf  USD 2.56  0.30  10.49%   
The etf retains a Market Volatility (i.e., Beta) of -1.88, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning GRI Bio are expected to decrease by larger amounts. On the other hand, during market turmoil, GRI Bio is expected to outperform it.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days GRI Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Etf's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The recent confusion may also be a sign of long-lasting up-swing for the Etf traders. ...more
Last Split Factor
1:28
Last Split Date
2026-01-26
1
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis
12/10/2025
2
GRI Bio Announces Pricing of 8,000,000 Million Public Offering
12/11/2025
3
GRI Bio Announces Closing of 8.0 Million Public Offering
12/12/2025
4
Acquisition by Hertz Walter Marc of 129730 shares of GRI Bio at 0.6857 subject to Rule 16b-3
01/06/2026
5
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
01/08/2026
6
GRI Bio To Carry Out 1-for-28 Reverse Stock Split On January 26th, 2026 -
01/23/2026
7
Wall Street Zen Downgrades GRI Bio to Strong Sell
02/02/2026

GRI Bio Relative Risk vs. Return Landscape

If you would invest  4,704  in GRI Bio on November 5, 2025 and sell it today you would lose (4,449) from holding GRI Bio or give up 94.58% of portfolio value over 90 days. GRI Bio is generating negative expected returns assuming volatility of 11.6214% on return distribution over 90 days investment horizon. In other words, majority of equities are less volatile than GRI, and most equities are expected to generate higher returns over the next 90 days.
  Expected Return   
       Risk  
Considering the 90-day investment horizon GRI Bio is expected to under-perform the market. In addition to that, the company is 15.32 times more volatile than its market benchmark. It trades about -0.33 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.1 per unit of volatility.
Below is the normalized historical share price chart for GRI Bio extending back to February 10, 2021. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of GRI Bio stands at 2.56, as last reported on the 3rd of February, with the highest price reaching 2.56 and the lowest price hitting 2.55 during the day.
IPO Date
10th of February 2021
200 Day MA
40.0694
50 Day MA
22.0696
Beta
(1.25)
 
Covid
 
Interest Hikes

GRI Bio Target Price Odds to finish over Current Price

The tendency of GRI Etf price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 2.56 90 days 2.56 
about 87.5
Based on a normal probability distribution, the odds of GRI Bio to move above the current price in 90 days from now is about 87.5 (This GRI Bio probability density function shows the probability of GRI Etf to fall within a particular range of prices over 90 days) .
Considering the 90-day investment horizon GRI Bio has a beta of -1.88. This usually indicates as returns on its benchmark rise, returns on holding GRI Bio are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, GRI Bio is expected to outperform its benchmark. Additionally GRI Bio has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   GRI Bio Price Density   
       Price  

Predictive Modules for GRI Bio

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as GRI Bio. Regardless of method or technology, however, to accurately forecast the etf market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the etf market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.102.0213.64
Details
Intrinsic
Valuation
LowRealHigh
2.3082.7294.34
Details
2 Analysts
Consensus
LowTargetHigh
586.04644.00714.84
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-19.88-19.88-19.88
Details

GRI Bio Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. GRI Bio is not an exception. The market had few large corrections towards the GRI Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold GRI Bio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of GRI Bio within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-3.48
β
Beta against Dow Jones-1.88
σ
Overall volatility
21.87
Ir
Information ratio -0.32

GRI Bio Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of GRI Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for GRI Bio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
GRI Bio generated a negative expected return over the last 90 days
GRI Bio has high historical volatility and very poor performance
GRI Bio has high likelihood to experience some financial distress in the next 2 years
GRI Biohas  700,747  shares shorted by GRI Bio investors is about 100% of outstending shares
Reported Net Loss for the year was (11.96 M) with profit before taxes, overhead, and interest of 0.
GRI Bio has about 183.82 M in cash with (10.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3.
Latest headline from thelincolnianonline.com: Wall Street Zen Downgrades GRI Bio to Strong Sell
The fund retains 99.63% of its assets under management (AUM) in equities

GRI Bio Fundamentals Growth

GRI Etf prices reflect investors' perceptions of the future prospects and financial health of GRI Bio, and GRI Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GRI Etf performance.

About GRI Bio Performance

By evaluating GRI Bio's fundamental ratios, stakeholders can gain valuable insights into GRI Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if GRI Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if GRI Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
The investment seeks investment results that correspond generally to the performance, before the funds fees and expenses, of an index called the Cohen Steers Global Realty Majors Index. Cohen Steers is traded on Archipelago Exchange in USA.
GRI Bio generated a negative expected return over the last 90 days
GRI Bio has high historical volatility and very poor performance
GRI Bio has high likelihood to experience some financial distress in the next 2 years
GRI Biohas  700,747  shares shorted by GRI Bio investors is about 100% of outstending shares
Reported Net Loss for the year was (11.96 M) with profit before taxes, overhead, and interest of 0.
GRI Bio has about 183.82 M in cash with (10.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3.
Latest headline from thelincolnianonline.com: Wall Street Zen Downgrades GRI Bio to Strong Sell
The fund retains 99.63% of its assets under management (AUM) in equities

Other Information on Investing in GRI Etf

GRI Bio financial ratios help investors to determine whether GRI Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GRI with respect to the benefits of owning GRI Bio security.